Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and Trabectedin in Advanced Liposarcoma and Leiomyosarcoma
NCT03074318Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2017
- Primary completion
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in leiomyosarcoma (LMS), Liposarcoma, sponsored by Fred Hutchinson Cancer Center. Started Sep 2017; status: terminated.
02
Drugs
avelumab
03
Conditions
leiomyosarcoma (LMS)Liposarcoma
Beyond the preview
Go deeper on NCT03074318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03074318.